DBV Technologies (NASDAQ:DBVT) Stock Price Passes Above 50 Day Moving Average – Here’s What Happened

DBV Technologies S.A. (NASDAQ:DBVT)’s share price crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $18.47 and traded as high as $23.53. DBV Technologies shares last traded at $21.61, with a volume of 395,621 shares traded.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on DBVT shares. Wall Street Zen lowered DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research report on Wednesday, December 17th. Citizens Jmp lifted their price target on shares of DBV Technologies from $21.00 to $45.00 and gave the stock a “market outperform” rating in a report on Wednesday, December 17th. Cantor Fitzgerald set a $48.00 price objective on DBV Technologies in a report on Wednesday, December 17th. Finally, Guggenheim restated a “buy” rating and issued a $51.00 target price (up from $35.00) on shares of DBV Technologies in a research note on Wednesday, December 17th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $35.38.

DBV Technologies Trading Down 5.9%

The business has a fifty day moving average of $18.47 and a 200-day moving average of $13.99. The firm has a market cap of $867.86 million, a PE ratio of -4.18 and a beta of -1.17.

Insider Buying and Selling

In related news, major shareholder Bpifrance Epic sold 2,076,990 shares of the business’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $4.85, for a total transaction of $10,073,401.50. Following the completion of the transaction, the insider directly owned 8,595,472 shares in the company, valued at $41,688,039.20. The trade was a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.44% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. GAMMA Investing LLC boosted its stake in shares of DBV Technologies by 38.4% in the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after buying an additional 744 shares during the last quarter. New York State Common Retirement Fund purchased a new position in DBV Technologies during the third quarter valued at $34,000. Two Sigma Investments LP purchased a new position in DBV Technologies during the 3rd quarter valued at approximately $167,000. Citadel Advisors LLC bought a new stake in shares of DBV Technologies in the 3rd quarter worth about $220,000. Finally, DLD Asset Management LP bought a new stake in DBV Technologies in the third quarter worth $250,000. 71.74% of the stock is owned by institutional investors.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.